A review of immune-related adverse events associated with immunotherapy / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 17-21, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-799029
ABSTRACT
Immune checkpoint inhibitors have been approved for clinical application in China. However, the increased immune-related adverse event (irAE) needs more attention. This review summarized the incidence, characteristic clinical manifestation and treatment of irAEs associated with programmed cell death protein-1(PD-1) and programmed cell death ligand-1(PD-L1) inhibitors. To have a deep insight into irAE, the potential mechanisms, the different incidences of cancer types, influencing factors and the direction of future research were also discussed here to provide guidance for clinical oncologist to identify and monitor irAE.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Guia de Prática Clínica
/
Estudo prognóstico
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS